Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Leukemia 2Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × Interferon alpha-2 × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡